CASE REPORT
A 14-year-old boy with a known history of NF1 and prior treatment for optic glioma presented with a two day history of severe headaches and vomiting that suddenly occurred while he was swimming. At age four, he had undergone craniotomy with debulking of a large, low grade chiasmatic glioma causing visual failure. Postoperatively he underwent cycles of chemotherapy with carboplatin and vincristine until he developed carboplatin allergy. He then received three cycles of vincristine and etoposide. Recurrent tumor and radiological progression was documented three years later, and he received weekly vinblastine for one year. Following this chemotherapy regimen, he experienced further progression and was treated with temozolomide for 16 months. The child's tumor was stable off chemotherapy for two years prior to his presentation on this occasion.
In the emergency room, his neurological exam was unremarkable except for his being legally blind from his optic glioma, and a mild left pronator drift. Computed tomogram (CT) followed by magnetic resonance image (MRI) revealed a right temporal intracerebral hemorrhage with midline shift remote from the chiasmatic tumor ( Figure 1A-B) . No vascular malformations or aneurysms were seen, but a nodular lesion in the superior temporal gyrus which enhanced with contrast administration could be seen. On the second day after admission, he developed a generalized, tonic-clonic seizure with a decreasing level of consciousness. He was taken to surgery emergently at which a right fronto-temporal craniotomy was performed, and the temporal hematoma was evacuated. Intraoperatively, the child became hemodynamically unstable from blood loss, and attempts to remove the superior temporal gyral lesion were abandoned. The bone flap was left out. A post-operative angiogram did not reveal a vascular lesion. The patient was discharged home eight days after admission in good condition with plans to replace the bone flap in eight weeks.
Seventeen days after discharge, the patient returned to the hospital with sudden onset of severe headache. The patient was alert and oriented with a left facial palsy and left hemiparesis. His craniectomy site was now bulging. An urgent CT revealed a rapidly enlarging right temporal hemorrhagic lesion with associated parenchymal hemorrhage ( Figure 1C-D) . The patient was taken back to the operating room for evacuation of the new hematoma, and surrounding brain tissue including the right superior temporal gyral lesion. He tolerated this procedure well, but required a ventriculoperitoneal shunt for a cerebrospinal fluid (CSF) disturbance in the post-operative period. The neuropathology of the submitted specimens revealed a cellular tumour composed of elongated cells having an abundant eosinophilic cytoplasm with centrally located and blunt-end, cigar-shaped nuclei. The tumour cells merged with the blood vessel wall and were arranged in a fascicular growth pattern in which the bundles intersected at right angles. The tumour showed high mitotic activity and recent hemorrhage. By in situ hybridization analysis, Epstein Barr infection was excluded. A diagnosis of intracranial leiomyo-sarcoma was made ( Figure 2 ).
The patient was discharged home in good condition without new neurological deficit, and returned six months later for bone flap replacement. Staging studies, including a spinal MRI, chest, and abdominal CTs, showed no tumour elsewhere making the diagnosis of metastatic leiomyosarcaroma unlikely. He received postoperative chemotherapy with two cycles of ICE (ifosfamide, carboplatin, and etoposide) and then proceeded to focal radiation using intensity modulated radiation therapy to the right frontotemporal region. He received concomitant oral etoposide during radiation therapy for two cycles, and this was followed by four additional cycles of ICE chemotherapy. He has been well without evidence of tumour recurrence at two years ( Figure 3 ).
DISCUSSION
Neurofibromatosis type 1 is a condition that represents a major risk factor for malignancy, particularly malignant peripheral nerve sheath tumours, gliomas and leukemias. The patient described in this case report represents a typical pediatric NF1 patient. The patient was followed closely and treated for an optic chiasmatic glioma in early childhood. Surveillance studies over time failed to demonstrate the development of a new intracranial mass lesion. The acute onset of headache and vomiting was the primary indication of an underlying structural abnormality in the brain.
Neurofibromatosis type 1 has been classified as an inherited predisposition syndrome to cancer. Both children and adults are at risk of developing a variety of benign and malignant tumors 7 . Fortunately the most common tumours found in these patients are benign, usually neurofibromas and optic gliomas 1 . Patients with NF1 have a three to five times greater risk of developing a malignancy than the general population 4 . Both CNS and non-CNS malignant tumours are associated with a higher frequency in NF1 8 . Associated non-CNS tumours reported with a higher than expected incidence include pheochromocytoma, Wilm's tumour, rhabdomyosarcoma, soft-tissue sarcoma, and leukemia 3, 9, 10 . Intracranial lesions of the CNS, particularly unidentified bright objects, and gliomas are typically followed with serial MRI studies in patients with NF1. Optic pathway gliomas are found in approximately 15% of NF1 patients 11 . Most children are asymptomatic, but they can manifest with symptoms of decreased visual acuity, visual field defects, or precocious puberty 12 . Aside from optic gliomas, astrocytomas of the cerebrum, brainstem, and cerebellum are the most common intracranial tumours encountered in NF1 3, 13 . In addition to these tumours, many reports of other intracranial tumours occurring in patients with NF1 can be found in the literature. Some of these intracranial tumours include medulloblastoma, dysembryoplastic neuroepethelial tumour, neurocytoma and soft-tissue sarcomas 3 . Soft-tissue sarcomas represent about 8% of all malignant tumours of children and adolescents with NF1 14 . The most common neurogenic sarcoma, the malignant peripheral nerve sheath tumour (MPNST) occurs in upwards of 10% of NF1 patients 15 . Malignant peripheral nerve sheath tumours contribute significantly to the reduced life-span of NF1-patients. Nonneurogenic sarcomas like rhab-domyosarcoma accounts for about half of soft tissue sarcoma cases 14 . Soft tissue sarcomas of the central nervous system are uncommon. The vast majority of these cases are secondary
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Figure 1: A/B. Axial T2-weighted MRI depicting a right temporal intracerebral hemorrhage with midline shift remote from a chiasmatic tumor. There is also a nodular pouch like lesion in the superficial temporal region with minimal contrast enhancement. C/D. Axial CT with contrast 25 days after initial treatment reveals a rapidly enlarging right temporal hemorrhagic lesion with associated parenchymal hemorrhage. There is also increased subfalcine herniation and a subgaleal fluid collection at the site of the craniectomy.
tumours spread from other primary sites. Primary intracranial sarcomas are especially rare 16 . Sporadic cases of intracranial rhabdomyosarcoma, leiomyoma, medulloblastoma with smooth muscle differentiation and leiomyosarcoma have been reported 3, 17, 18 . These intracranial sarcomas are thought to have a leptomeningeal as well as vascular origin. Many have found to arise from the dura matter and cerebral vascular epithelium 19 . Soft tissue sarcomas are commonly associated with NF1. Non-CNS rhabdomyosarcoma is the most frequent of these sarcomas. Leiomyosarcoma is another soft-tissue sarcoma found in NF1, but typically it arises from the abdominal cavity [20] [21] [22] . Other cases of hepatic and bladder leiomyosarcoma in NF1 patients have also been reported 23, 24 . To our knowledge, the child we present here represents the first patient with NF1 and an intracranial leiomyosarcoma. Interestingly, in non-NF1 patients with malignant mesenchymal tumours, H-ras-1 mutations have been found in malignant fibrous histiocytoma, leiomyosarcoma and embryonal rhabdomyosarcoma 25 . As the NF1 gene encodes a tumour suppressor which inactivates ras, a possible underlying genetic mechanism is conceivable in the case we report here.
Intracranial leiomyosarcomas are exceedingly rare, the majority of which represent metastatic disease 11 . To date, none of the reported cases of primary cerebral leiomyosarcoma have been associated with patients with NF1. Of the reported cases of intracranial leiomysoarcomas, many have been observed in immunocompromised patients. The association of these neoplasms with AIDS patients, post-transplantaion patients, and patients undergoing radiation therapy has been well documented 26, 27 . Many of these cases are associated with Epstein-Barr virus (EBV) infections prior to the onset of tumorigenesis 27 . The patient in our case was likely immunocompromised during his chemotherapy treatments. The pathological report however indicates that the tumour was EBV negative by in situ hybridization studies. There are case reports of EBV-negative intracranial leiomyosarcomas in a 13-year-old boy and 26-year-old man 28, 29 . The available data on NF1 and the pathogenesis of leiomyosarcomas suggest several possible mechanisms that might have contributed to the development of this rare tumour in this patient. Some of the possible pathological processes include: 1) De novo intracranial leiomyosarcoma formation independent of NF1; 2) intracranial leiomyosarcoma associated with NF1; 3) intracranial leiomyosarcoma secondary to prolonged immunosuppression from chemotherapy, and 4) a chemotherapy-induced leiomyosarcoma in a patient with NF-1. Regarding this latter possibility, it is known that chemotherapy is far more potent than radiation therapy at inducing cancers such as leukemias 30 . This is particularly true following treatments with alkylating agents and topoisomerase II inhibitors. As for solid tumours, a causal link has been made between the administration of cyclophosphamide and bladder cancer 31 in patients treated for non-Hodgkins lymphoma, and between alkylating agents and bone sarcomas in children 32 . There is also evidence for the induction of breast cancers with alkylating agents in patients treated for Hodgkin's lymphoma 33 . The optimum treatment of the patient with an intracranial leiomyosarcoma includes the administration of sarcoma-based chemotherapy and radiation therapy. The decision to irradiate the brain of a child with NF1 is undertaken with some caution as there have been reports of an increased incidence of vasculopathy and secondary tumours following radiation in this patient population 34 . In addition, the decision to use alkylating agents in the NF1 population should be done with caution because of the increased risk of secondary leukemia. While follow-up is short, at two years our patient is doing well without tumor recurrence or the development of new intracranial tumours.
In summary we present a case of an intracranial leiomyosarcoma in a pediatric patient with NF1. The presence of this soft tissue sarcoma in the intracranial compartment in a child heavily pre-treated with chemotherapy for optic glioma may suggest a pathogenetic mechanism in a patient with an underlying neurogenetic syndrome. 
